An Open-label Extension Study to Evaluate the Long-term Safety of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

时间窗: From the start of study drug administration up to 12 weeks after the last dose of study drug (approximately up to 3 years)

An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received investigational product. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with onset date after the first dose of mavrilimumab 100 mg.

Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)

时间窗: From the start of study drug administration in the study up to 12 weeks after the last dose of study drug (approximately up to 3 years)

Laboratory parameters included hematology, serum chemistry and urinalysis recorded as TEAEs. Clinical laboratory abnormalities recorded as TEAEs were reported.TEAEs were defined as AEs with onset date after the first dose of mavrilimumab 100 mg.

Number of Participants With Vital Sign Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)

时间窗: From the start of study drug administration in the study up to 12 weeks after the last dose of study drug (approximately up to 3 years)

Vital sign assessments included blood pressure, pulse rate, temperature, weight and respiration rate. Vital sign abnormalities recorded as TEAEs were reported. TEAEs were defined as AEs with onset date after the first dose of mavrilimumab 100 mg.

Number of Participants With Abnormal Electrocardiogram (ECG) Findings Reported as TEAEs

时间窗: From the start of study drug administration in the study up to 12 weeks after the last dose of study drug (approximately up to 3 years)

The 12-lead ECG data were summarized and evaluated. TEAEs related to abnormal ECG findings were recorded and reported. TEAEs were defined as AEs with onset date after the first dose of mavrilimumab 100 mg.

Number of Participants With Forced Expiratory Volume in 1 Second (FEV1) Outside Threshold Values

时间窗: From Week 24 to Week 130 at specified time points

Pulmonary function testing was performed by spirometry to assess forced expiratory volume in 1 second (FEV1). FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration.The percentage (%) of predicted values of these pulmonary function tests were calculated based on decrease from baseline and categorized as less than or equal to (=\<)15% reduction from baseline, greater than (\>)15% to =\<20% reduction from baseline, \>20% reduction from baseline and \>20% reduction to \<80%. The threshold values refer to baseline values for each participant.

Number of Participants With Forced Expiratory Volume in 6 Seconds (FEV6) Outside Threshold Values

时间窗: From Week 24 to Week 130 at specified time points

Pulmonary function testing was performed by spirometry to assess forced expiratory volume in 6 seconds (FEV6). FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. The percentage of predicted values of these pulmonary function tests were calculated based on decrease from baseline and categorized as =\<15% reduction from baseline, \>15% to =\<20% reduction from baseline, \>20% reduction from baseline and \>20% reduction to \<80%. The threshold values refer to baseline values for each participant.

Number of Participants With Forced Vital Capacity (FVC) Outside Threshold Values

时间窗: From Week 24 to Week 156 at specified time points

Pulmonary function testing was performed by spirometry to assess forced vital capacity (FVC). FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. The percentage of predicted values of these pulmonary function tests were calculated based on decrease from baseline and categorized as =\<15% reduction from baseline, \>15% to =\<20% reduction from baseline, \>20% reduction from baseline and \>20% reduction to \<80%. The threshold values refer to baseline values for each participant.

Number of Participants With Clinically Meaningful Change in Borg Dyspnea Score Considered as an AE

时间窗: From Week 0 to Week 132 at specified time points

Borg dyspnea score was a validated participant reported outcome assessing participant's perceived difficulty in breathing (dyspnea). The score ranges from 0 (nothing at all) to 10 (maximal difficulty). Higher scores indicated greater difficulty in breathing.

Oxygen Saturation Levels by Pulse Oximetry

时间窗: From Week 0 to Week 132 at specified time points

Oxygen saturation measured by pulse oximetry which measures the concentration of oxygen in the blood.

Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)

时间窗: From Week 12 to Week 156 at specified time points

DLCO is a pulmonary function testing that measures partial pressure difference between inspired and expired carbon monoxide.